Welcome to our dedicated page for Aethlon Medical news (Ticker: AEMD), a resource for investors and traders seeking the latest updates and insights on Aethlon Medical stock.
Aethlon Medical, Inc. (NASDAQ: AEMD) is a clinical-stage medical device innovator advancing the Hemopurifier® - a therapeutic filtration device targeting cancer-enabling exosomes and life-threatening viruses. This page provides investors and medical professionals with essential updates on clinical developments, regulatory progress, and strategic initiatives.
Key resources include press releases detailing trial protocols, ethics committee approvals, and operational milestones. Users will find verified information on oncology applications for treatment-resistant cancers and infectious disease programs, all presented in compliance with financial disclosure standards.
Content highlights encompass FDA communications, trial enrollment updates, and peer-reviewed research collaborations. The curated news collection serves as a reliable reference for tracking the Hemopurifier®'s progress through clinical validation stages and potential therapeutic applications.
Bookmark this page for direct access to Aethlon Medical's official announcements, including breakthrough device designations and international trial expansions. Check regularly for updates on this pioneering approach to blood filtration technology and its implications for cancer immunotherapy advancement.
Aethlon Medical (NASDAQ: AEMD) reported early clinical observations from the first three patients in an Australian safety, feasibility and dose‑finding trial of the Hemopurifier in cancer patients refractory to anti‑PD‑1 therapy. Investigators observed directional decreases in certain extracellular vesicles (EVs), PD‑L1+ EV subsets, and 7 of 10 measured microRNAs in two patients after a single 4‑hour treatment, plus increases in total and subset T cells in some participants. Changes generally returned to baseline in 1–3 weeks.
The release cautions these are preliminary observations from three patients with limited follow‑up and are not evidence of clinical benefit.
Aethlon Medical (Nasdaq: AEMD) reported preliminary biological changes from the first cohort (3 patients) in its Australian safety, feasibility and dose‑finding oncology trial of the Hemopurifier.
Key observations after a single 4‑hour Hemopurifier treatment: decreases in large EVs and platelet‑derived EVs in two patients, EV PD‑L1 decreased in all three, 7 of 10 microRNAs decreased in two patients, and increases in total T cells, CD8, CD4 and tumor‑specific (CD137+) T cells were noted. EV and microRNA levels generally returned to baseline within 1–3 weeks.
The company emphasized caveats: a 3‑patient cohort with one withdrawal, single treatments only, directional descriptive results only, and no claim of clinical efficacy or dose response without larger trials.
Aethlon Medical (Nasdaq: AEMD), a medical therapeutic company focused on cancer and infectious disease treatments, has announced the pricing of a $4.5 million public offering. The offering consists of 5,000,000 shares of common stock (or pre-funded warrants) and warrants to purchase up to 5,000,000 additional shares at a combined price of $0.90 per share.
The accompanying warrants will have an exercise price of $0.90 per share, exercisable immediately with a five-year expiration term. The offering, expected to close around September 5, 2025, is being managed by Maxim Group LLC as the exclusive placement agent. Proceeds will fund general corporate purposes, including clinical trials, R&D, and working capital.
Aethlon Medical (NASDAQ: AEMD) has strengthened its intellectual property portfolio with two significant patent approvals for its Hemopurifier® device. The US Patent No. 12,409,260 for Long COVID treatment will issue on September 9, 2025, expiring in 2042, while the Unitary European Patent 4136453 for COVID-19-associated coagulopathy was issued July 9, 2025, expiring in 2041.
The Hemopurifier®, which holds FDA Breakthrough Device Designation, is designed to remove viruses, viral fragments, and tumor-derived extracellular vesicles from circulation. The company's IP portfolio includes 14 international patents for exosome removal and 4 US patents for microvesicular particle removal, with protection extending through 2031 in various European countries.
This development comes as the global medical device market, currently valued at $680 billion, is projected to exceed $1 trillion within 10 years at a 6% CAGR, highlighting the critical importance of IP in the medtech sector.
Aethlon Medical (Nasdaq: AEMD) has secured two significant patents for its Hemopurifier® device: U.S. Patent No. 12,409,260 for Long COVID treatment and European Patent 4136453 for COVID-19-associated coagulopathy (CAC) treatment. The U.S. patent, which expires in 2042, covers treating patients with reduced viral load but persistent Long COVID symptoms and the removal of circulating COVID-19 spike protein. The European patent, expiring in 2041, protects the Hemopurifier's use in treating CAC patients without circulating viral particles.
The U.S. patent received an additional 385-day term adjustment. CEO James Frakes emphasized that while the Hemopurifier® remains in R&D for Long COVID applications, these patents strengthen their intellectual property portfolio in areas with significant unmet medical needs.
Aethlon Medical (Nasdaq: AEMD) reported fiscal Q1 2025 results and provided updates on its Hemopurifier cancer trial. The company successfully completed the first cohort of its Australian cancer trial with no device-related serious adverse events. The trial protocol was amended to broaden patient eligibility for anti-PD-1 therapy.
Key financial highlights include a 31.6% reduction in operating expenses to $1.8 million, down from $2.6 million in the prior year. Cash balance stood at $3.8 million as of June 30, 2025. Preclinical data showed 98.5% removal of platelet-derived extracellular vesicles in simulated treatments.
The company discontinued its planned India trial to focus resources on the Australian study. Additionally, Aethlon presented promising Long COVID research data at the Keystone Symposium, demonstrating the Hemopurifier's potential broader applications.
Aethlon Medical (Nasdaq: AEMD), a clinical-stage medical device company, will release its fiscal Q1 2025 financial results on August 13, 2025 at 4:15 p.m. ET, followed by a conference call at 4:30 p.m. ET.
The company's main product, the Hemopurifier®, is an investigational medical device designed to remove enveloped viruses and tumor-derived extracellular vesicles from circulation. The device holds FDA Breakthrough Device Designation for treating advanced cancer patients unresponsive to standard therapy and life-threatening viruses without approved treatments.
Aethlon Medical (Nasdaq: AEMD) announced positive safety review results from the independent Data Safety Monitoring Board (DSMB) for its ongoing clinical trial AEMD-2022-06 of the Aethlon Hemopurifier®. The trial is evaluating the device's safety and optimal dosing in cancer patients with stable or progressive disease while on Pembrolizumab or Nivolumab treatment.
The DSMB reviewed data from the initial three-patient cohort, who each received a single 4-hour Hemopurifier treatment, finding no safety concerns or serious adverse events. The board recommended advancing to Cohort 2, where participants will receive two Hemopurifier treatments over one week. The trial aims to enroll 9-18 patients across three Australian clinical sites.
The study targets patients among the 60-70% who don't respond well to anti-PD-1 immunotherapy, with findings intended to inform future Premarket Approval studies.
Aethlon Medical (Nasdaq: AEMD) reported financial results for Q4 FY2025 and provided corporate updates. Key highlights include treatment of three patients in the Hemopurifier® cancer trial in Australia, regulatory approval in India, and significant operational cost reductions. The company's cash balance stood at $5.5 million as of March 31, 2025.
Operating expenses decreased by 26% to $9.3 million from $12.6 million year-over-year. Preclinical data showed 98.5% removal of platelet-derived EVs in simulated Hemopurifier® treatment. The company is expanding research into Long COVID applications through collaboration with UCSF, addressing a market affecting 44-48 million people in the US.
FAQ
What is the current stock price of Aethlon Medical (AEMD)?
What is the market cap of Aethlon Medical (AEMD)?
